Novartis Receives FDA Approval for Tevimbra in Cervical Cancer

Novartis today announced that the FDA has approved Tevimbra (tislelizumab-jsgr) in combination with chemotherapy with or without bevacizumab for the treatment of adults with persistent, recurrent, or metastatic cervical cancer. In the Phase 3 RATIONALE-309 trial, Tevimbra plus chemotherapy demonstrated a statistically significant improvement in overall survival compared to chemotherapy alone. The median OS was 19.8 months for Tevimbra plus chemotherapy versus 15.2 months for chemotherapy alone. This approval provides patients with cervical cancer a new first-line treatment option.